Holen Sie sich die Stockscreener-App
8.525
8.63%
0.705
Immunitybio Inc Aktie (IBRX) Neueste Nachrichten
ImmunityBio Stock Soars 295% YTD: Time to Buy, Hold or Sell? - Zacks Investment Research
ImmunityBio completes NK cell manufacturing programs - Investing.com
Single apheresis yields 5B NK cells in ImmunityBio cancer program - Stock Titan
Why ImmunityBio Stock Is Soaring Today - AOL.com
ImmunityBio’s (IBRX) Bladder Cancer sBLA Resubmission Tests The Depth Of Its Immuno‑Oncology Strategy - simplywall.st
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments - MarketBeat
Assessing ImmunityBio (IBRX) Valuation After FDA Acknowledges Resubmitted ANKTIVA Bladder Cancer Filing - simplywall.st
ImmunityBio (NASDAQ:IBRX) Stock Price Up 3.2%What's Next? - MarketBeat
Immunitybio stock initiated at Buy by BTIG with $13 target - Investing.com
Lucid Tops The Most-Shorted Stock List—Here Are 9 More Short Targets - Benzinga
IBRX Stock Rout Deepens: Founder Points To Cancer-Fighting Cell Bank Data As Investors Look For Catalyst - Stocktwits
IBRX Stock Falls -23% In 6-Day Spree On Profit-Taking After 500% YTD Gain - Trefis
IBRX Stock Down 10% This Week, But Its CEO Just Outlined 3 Reasons Bull Case Is Intact - Stocktwits
ImmunityBio Earnings Call: ANKTIVA Surge Amid High Burn - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
ImmunityBio Faces Potential Setback Amid Director’s Share Sale and Investigation - timothysykes.com
ImmunityBio’s Immunotherapy ANKTIVA Sparks Revenue Surge as Global Expansion Accelerates (IBRX, NNVC) - marketscreener.com
Is It Time To Reassess ImmunityBio (IBRX) After Its Recent Share Price Surge - simplywall.st
FDA Review And Saudi Approval Keep ANKTIVA Central To ImmunityBio Story - Yahoo Finance
Piper Sandler Keeps an Overweight Rating on ImmunityBio, Inc. (IBRX) - Finviz
IBRX stock declines — ImmunityBio resubmits Anktiva application to FDA with additional data - MSN
ImmunityBio (NASDAQ:IBRX) Shares Down 2.5%Should You Sell? - MarketBeat
ImmunityBio's (IBRX) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Can IBRX Stock Snap Its 4-Day Slide? Founder Promises ‘Game-Changer’ Anktiva Data As FDA Speeds Drug Reviews - Stocktwits
Behind the Scenes of ImmunityBio's Latest Options Trends - Benzinga
IBRX Stock Declines — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data - Stocktwits
ImmunityBio Announces FDA Resubmission For Expanded Use Of Lead Drug - Bitget
ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data - The Malaysian Reserve
IBRX Stock Declines Pre-Market — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data - Asianet Newsable
ImmunityBio Stock Sinks as FDA Review Drags On - TipRanks
ImmunityBio resubmits bladder cancer application to FDA - Investing.com
ImmunityBio resubmits sBLA to FDA for Anktiva plus BCG - TipRanks
FDA seeks more bladder cancer data; ImmunityBio resubmits ANKTIVA bid - Stock Titan
ImmunityBio’s Stock Sees a Huge Boost - Los Angeles Business Journal
ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results - MSN
How dovish Fed policy supports ImmunityBio Inc. (26CA) stock2026 Technicals & Weekly Market Pulse Alerts - Naître et grandir
ImmunityBio (IBRX) soars to new high on Anktiva future expansion - MSN
Vanguard Group Inc. Boosts Stock Position in ImmunityBio, Inc. $IBRX - MarketBeat
How ImmunityBio Inc. stock valuations compare to rivalsJuly 2025 Drop Watch & Fast Entry High Yield Tips - Naître et grandir
Rafferty Asset Management LLC Grows Stake in ImmunityBio, Inc. $IBRX - MarketBeat
ImmunityBio (NASDAQ:IBRX) Trading Down 3.2%Time to Sell? - MarketBeat
H.C. Wainwright Raised Its Price Target on ImmunityBio, Inc. (IBRX) to $15 from $10 and Maintains a Buy Rating - Bitget
ImmunityBio ANKTIVA Milestones Reshape Growth Outlook And Risk Profile - Sahm
IBRX Founder’s ‘Congrats’ To GSK Sparks Debate After FDA Fast Drug Approvals — Retail Slams Big Pharma Bias Over Anktiva - Stocktwits
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 - AOL.com
ImmunityBio’s Q4 Revenue Gets A Lift From ANKTIVA Sales – IBRX Stock Gains 11% - Stocktwits
Forget ImmunityBio: This Big‑Cap Pharma Is the Safer Play on Next‑Gen Cancer Therapies - Yahoo Finance
ImmunityBio Bladder Cancer Milestone Raises Questions On Global ANKTIVA Rollout - Yahoo Finance
ImmunityBio (IBRX) Is Down 5.8% After ANKTIVA Rollout Fuels Revenue Jump And Narrower Losses - Yahoo Finance
IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? - Stocktwits
Piper Sandler Maintains Overweight on ImmunityBio (IBRX) March 2026 - Meyka
ImmunityBio Shares Retreat Despite Strong Commercial Momentum - AD HOC NEWS
ImmunityBio (NASDAQ:IBRX) Stock Price Down 10.2%What's Next? - MarketBeat
ImmunityBio Director’s Share Sale Spurs Investigations: Stock Faces Downturn - timothysykes.com
IMMUNITYBIO, INC. (IBRX) Stock, Price, News, Quotes, Forecast and Insights - MSN
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):